Immuvera Therapeutics is an innovative Norwegian biotech company dedicated to developing advanced cancer immunotherapies for companion animals, with a vision to translate these treatments for human use. At the forefront of veterinary oncology, Immuvera has pioneered breakthrough technologies, such as its proprietary Nebumet system, specifically targeting lung metastases in dogs. The company's portfolio includes both off-the-shelf and personalized immunotherapy options aimed at treating solid tumors in dogs, addressing a significant unmet need in veterinary medicine, where cancer remains the leading cause of death.

By leveraging insights from comparative oncology, Immuvera aims to enhance therapeutic solutions for both canine patients and their human counterparts. The company's treatments are currently progressing toward clinical trials, and they actively seek partnerships with veterinary clinics and research institutions to accelerate innovation. With a passionate team experienced in cutting-edge cancer research, Immuvera Therapeutics is poised to redefine cancer care for pets, offering hope to pet owners and valuable advancements in the broader field of oncology.